Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

60.0%

-26.6% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

7 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

7(53.8%)

N/A

4(30.8%)

Phase 2

2(15.4%)

13Total

Phase 1(7)

N/A(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06047977Phase 1Recruiting

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Role: collaborator

NCT05944562Phase 1Active Not Recruiting

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Role: collaborator

NCT05641961Not ApplicableActive Not Recruiting

Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care

Role: collaborator

NCT03900793Phase 1Recruiting

Losartan + Sunitinib in Treatment of Osteosarcoma

Role: collaborator

NCT06593106Not ApplicableActive Not Recruiting

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Role: collaborator

NCT06580106Recruiting

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Role: collaborator

NCT06945042Not ApplicableRecruiting

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Role: collaborator

NCT07200089Phase 1Recruiting

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Role: collaborator

NCT04887935Phase 1Terminated

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Role: collaborator

NCT07379125Phase 1Recruiting

Therapeutic RSK1 Targeting in Myelofibrosis

Role: collaborator

NCT05837455Phase 2Recruiting

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Role: collaborator

NCT06559709Not ApplicableCompleted

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Role: collaborator

NCT02324543Phase 1Completed

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Role: collaborator

NCT01459614Phase 2Completed

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Role: collaborator

NCT02558205Withdrawn

Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry

Role: collaborator

All 15 trials loaded